OKYO
OKYO Pharma Ltd - New (OKYO)
Healthcare • NASDAQ • $1.63+0.62%
- Symbol
- OKYO
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $1.63
- Daily Change
- +0.62%
- Market Cap
- $85.54M
- Trailing P/E
- N/A
- Forward P/E
- -8.15
- 52W High
- $3.35
- 52W Low
- $1.32
- Analyst Target
- $9.00
- Dividend Yield
- N/A
- Beta
- -0.05
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase II clinical trials for the treatment of dry eye disease; in Phase II clinical trial to treat neuropathic corneal pain; and is in preclinical trial to treat allergic conjunctivitis and uveitis. The company is also developing OK-201 for the treatment acute and chronic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
Company websiteResearch OKYO on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.